One of the key takeaways from the meeting, and from phase I of CHL UK, was that we tested and learned together for a whole year, but it’s now time to put our energy into what works.
Novartis has renewed its pledge with the World Health Organization (WHO) to work to end leprosy by extending its donation of multidrug therapy (MDT) medicines to treat leprosy through the year 2020. This five-year agreement includes treatments worth more than USD 40 million and up to USD 2.5 million to support the WHO in handling the donation and logistics. Overall it is expected that the program will reach an estimated 1.3 million patients during the next five years. This is part of the company’s commitment in 2012 to the London Declaration on Neglected Tropical Diseases.
Everyone’s financial journey is different. We make intentional efforts to meet the individual needs of clients and communities through a diverse range...
The SCS Kingfisher certification mark is showing up on an increasing number of products around the world. It differentiates companies that are making...
